Therapy Areas: AIDS & HIV
NantKwest and ImmunityBio Team On Joint Development, Manufacturing, Marketing, and Commercialisation of COVID-19 Vaccine and Related Therapeutics
24 August 2020 - - US-based natural killer cell-based therapeutics company NantKwest, Inc. (NASDAQ: NK) and US-based immunotherapy company ImmunityBio have signed a definitive agreement to jointly develop, manufacture, market, and commercialise therapeutics and vaccines for combating the COVID-19 pandemic, the companies said.

Under the terms of the definitive agreement, the two companies agree to share equally the costs incurred after August 21, 2020 of development, manufacturing, marketing, and commercialisation of the products each is developing related to COVID-19.

Should a product be commercialised successfully, the companies have agreed to a 60-40 percentage split of net profits, with the larger share going to the company that developed the product.

The agreement also details the structure of shared governance of the joint collaboration.

The two product candidates currently in development under the agreement are a mesenchymal stem cell therapeutic from NantKwest, whose goal is to reduce the time a critically ill patient spends on a ventilator; and a COVID-19 vaccine product from ImmunityBio, which is anticipated to soon enter into a phase I clinical trial.

NantKwest (NASDAQ: NK) is an innovative, clinical-stage immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is a producer of clinical dose forms of off-the-shelf natural killer cell therapies.

The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimised, activated NK cells--as well as their activity against a broad range of cancers--has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States.

By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest's goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies.

ImmunityBio, Inc. is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious disease.

The company's immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term "immunological memory."

This novel approach is designed to eliminate the need for high-dose chemotherapy, improve upon the outcomes of current CAR T-cell therapies, and extend beyond checkpoint inhibitors.

ImmunityBio's platform is based on the foundation of three separate modalities: antibody cytokine fusion proteins, synthetic immunomodulators, and second-generation vaccine technologies.

ImmunityBio's lead cytokine infusion protein, a novel interleukin-15 (IL-15) superagonist complex (Anktiva), has received Breakthrough Therapy and Fast Track Designations from the US Food and Drug Administration for BCG-unresponsive CIS non-muscle invasive bladder cancer (NMIBC).

Other indications currently at registration-stage trials include BCG-unresponsive papillary bladder cancer, first and second line lung cancer, triple-negative breast cancer, metastatic pancreatic cancer, recurrent glioblastoma, and soft tissue sarcoma in combination with the company's synthetic immune modulator (Aldoxorubicin).

ImmunityBio is also developing therapies, including vaccines, for the prevention and treatment of HIV, influenza, and the coronavirus SARS-CoV-2 with its second-generation human adenovirus vaccine platform.
Login
Username:

Password: